IMG-7289 in Patients With Essential Thrombocythemia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in
patients with essential thrombocythemia.
This study investigates the following:
- The safety and tolerability of IMG-7289
- The pharmacodynamic effect of IMG-7289